NCT03282344View on ClinicalTrials.gov

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 12, 2017

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
SARCOMA
Interventions
DRUG

NKTR-214

0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.

DRUG

Nivolumab

360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort), New York

77030

MD Anderson Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort), Houston

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Stanford University

OTHER

collaborator

Rockefeller University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER